Traws Pharma Files 8-K

Ticker: TRAW · Form: 8-K · Filed: Aug 18, 2025 · CIK: 1130598

Traws Pharma, Inc. 8-K Filing Summary
FieldDetail
CompanyTraws Pharma, Inc. (TRAW)
Form Type8-K
Filed DateAug 18, 2025
Risk Levellow
Pages3
Reading Time3 min
Sentimentneutral

Sentiment: neutral

Topics: 8-K, corporate-filing, pharmaceutical

TL;DR

Traws Pharma (fka Onconova) filed an 8-K on 8/18/25 covering Reg FD, other events, and financials.

AI Summary

Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K on August 18, 2025, reporting on events including a Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company, incorporated in Delaware, is in the Pharmaceutical Preparations industry and is located at 12 Penns Trail, Newtown, PA 18940.

Why It Matters

This filing provides an update on Traws Pharma's corporate activities and financial reporting, which is crucial for investors to understand the company's current status and regulatory compliance.

Risk Assessment

Risk Level: low — This is a routine 8-K filing that primarily reports on corporate events and financial statements without announcing significant new risks or material changes.

Key Players & Entities

  • Traws Pharma, Inc. (company) — Registrant
  • Onconova Therapeutics, Inc. (company) — Former company name
  • August 18, 2025 (date) — Date of report
  • 12 Penns Trail, Newtown, PA 18940 (location) — Company address
  • 267-759-3680 (phone_number) — Company phone number

FAQ

What specific events are covered under the 'Other Events' section of this 8-K filing?

The provided text does not detail the specific 'Other Events' covered in the filing, only that it is an item reported.

When did Traws Pharma, Inc. change its name from Onconova Therapeutics, Inc.?

The filing indicates a name change from Onconova Therapeutics, Inc. on May 26, 2009.

What is Traws Pharma, Inc.'s Standard Industrial Classification (SIC) code?

Traws Pharma, Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.

What is the Commission File Number for Traws Pharma, Inc.?

The Commission File Number for Traws Pharma, Inc. is 001-36020.

What is the fiscal year end for Traws Pharma, Inc.?

The fiscal year end for Traws Pharma, Inc. is December 31 (1231).

Filing Stats: 841 words · 3 min read · ~3 pages · Grade level 11.4 · Accepted 2025-08-18 07:01:10

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On August 18, 2025, Traws Pharma, Inc. (the "Company") began using a new corporate presentation. A copy of that corporate presentation is furnished as Exhibit 99.1 hereto and incorporated herein by reference. The presentation will also be posted to the Company's website. The information set forth under Item 7.01 of this Current Report on Form 8-K (this "Current Report"), including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.

01

Item 8.01 Other Events. On August 18, 2025, the Company issued a press release (the "Press Release") announcing receipt of approval from the Human Research Ethics Committee to proceed with a Phase 2 study to evaluate ratutrelvir, a ritonavir-free treatment in newly diagnosed COVID subjects. A copy of the Press Release is filed herewith as Exhibit 99.2 and is incorporated by reference into this Item 8.01.

Forward-Looking Statements

Forward-Looking Statements This Current Report, including Exhibits 99.1 and 99.2, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms "anticipates," "expects," "estimates," "believes," "will" and similar expressions, as they relate to the Company or its management, are intended to identify such forward-looking statements.

Forward-looking statements

Forward-looking statements in this Current Report, including Exhibits 99.1 and 99.2, or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission, reports to the stockholders of the Company and other publicly available statements issued or released by the Company involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management's best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Securities and Exchange Commission, each of which could adversely affect the Company's business and the accuracy of the forward-looking statements contained herein.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated August 18, 2025. 99.2 Investor Presentation, dated August 2025. 104 Cover Page Interactive Data File (embedded within the inline XBRL Document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 18, 2025 TRAWS PHARMA, INC. By: /s/ Iain Dukes Iain Dukes Interim Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.